Savara Inc. — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023; comparisons are with the year ended December 31, 2022. This is an annual report, not a separate fourth-quarter earnings report.
Business context and reporting period
Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Its sole program is molgramostim nebulizer solution, an inhaled GM-CSF biologic in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Savara has no product revenue and has not begun commercial operations.
Financial results and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $44.3 million | $27.9 million |
| General and administrative expense | $15.7 million | $10.9 million |
| Total operating expenses / operating loss | $60.0 million | $38.8 million |
| Other income, net | $5.3 million | $0.7 million |
| Net loss | $54.7 million | $38.2 million |
| Basic and diluted loss per share | $0.33 | $0.25 |
| Cash used in operating activities | $51.1 million | $34.6 million |
At year-end, cash and cash equivalents were $26.6 million and short-term investments were $135.7 million, totaling $162.3 million. Current assets were $165.9 million, current liabilities $10.6 million, and working capital approximately $155.4 million. Long-term debt had a carrying value of $26.3 million. Accumulated deficit was $393.4 million. Profitability and operating margins are not meaningful measures for the company’s current pre-revenue stage.
Material changes versus 2022
- Net loss increased by $16.5 million; operating expenses rose by $21.2 million.
- R&D expense rose 58.8%, mainly reflecting manufacturing and chemistry, manufacturing and controls work, IMPALA-2 trial activity, quality assurance, and personnel costs.
- G&A expense increased 43.4%, mainly due to added personnel and commercial-readiness activities.
- Higher interest income, associated with increased short-term investments and market rates, partially offset higher operating costs.
- Operating cash use increased by $16.5 million. Investing activities used $57.1 million, primarily reflecting purchases and maturities of short-term investments; financing activities provided $82.8 million.
- In July 2023, Savara raised approximately $74.9 million net in a registered direct offering of common stock and pre-funded warrants; it also received $8.8 million net from common-stock sales under its Evercore agreement. These financings increased share count and diluted existing holders.
Outlook, management commentary, and key risks
- Clinical outlook: IMPALA-2, a 48-week, placebo-controlled Phase 3 trial, completed enrollment in June 2023 with 164 patients. Top-line results were expected at the end of the second quarter of 2024. The trial’s primary efficacy time point is week 24, with efficacy and safety assessed through week 48.
- Prior trial context: The earlier IMPALA Phase 2/3 trial did not meet its primary endpoint. Savara cites favorable secondary and exploratory findings, but those results do not establish regulatory approval or guarantee success of IMPALA-2.
- Funding: Management stated that available capital was sufficient for planned activities and the financial statements say it was sufficient to fund operations for the twelve months after issuance on March 7, 2024. The company expects ongoing losses and may need additional capital for later development, approval, or commercialization; financing could dilute shareholders or be unavailable on acceptable terms.
- Manufacturing: Savara relies on outside suppliers. GEMA currently makes drug substance and Patheon makes drug product; in February 2024, Savara contracted with Fujifilm for further development and a process-performance-qualification manufacturing campaign. Alternate sources must demonstrate comparability and satisfy regulatory requirements.
- Debt and liquidity conditions: The loan is secured by substantially all assets other than intellectual property, which is subject to a negative pledge. It has floating-rate interest, restrictive covenants, and conditions tied to cash levels; covenant breaches could accelerate repayment. Principal payments are scheduled after the interest-only period, with maturity in April 2027.
- Other risks: Results depend heavily on the sole product candidate, regulatory review, trial outcomes, manufacturing execution, and future market access and reimbursement. Supply-chain exposure includes Argentina’s inflation, currency weakness, labor strikes, and social and political conditions, as well as geopolitical disruption. Savara reports no material pending litigation. It reported no material cybersecurity incidents to date.
- Commercial readiness: Savara launched a U.S. aPAP diagnostic blood test in December 2023 and expected a European disease-awareness and testing rollout in 2024. It has limited marketing capability and no sales organization.
Most important facts for investors to verify
- Whether IMPALA-2 results met the primary endpoint and support the safety and efficacy evidence needed for regulatory submissions.
- Whether the stated cash runway remains adequate after trial results, manufacturing work, regulatory requirements, and commercialization planning.
- Progress and cost of qualifying secondary drug-substance and drug-product manufacturers, including comparability and regulatory inspection readiness.
- Debt covenant compliance, cash thresholds, interest-rate exposure, and the timing of principal repayment obligations.
- Potential dilution from outstanding options, restricted stock units, pre-funded warrants, and future equity financing; Savara reported 138.1 million common shares outstanding at December 31, 2023 and 138.1 million as of March 7, 2024.